Resistance of influenza viruses to neuraminidase inhibitors - A review

Antiviral Research

Volumn 47, Issue 1, 2000, Pages 1-17

  McKimm Breschkin, Jennifer L ^a  

^a CSIRO   (Australia)

Author keywords

Influenza virus; Neuraminidase inhibitors; Resistance to neuraminidase inhibitors

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

DRUG EFFECT; DRUG SENSITIVITY; GENE MUTATION; INFLUENZA VIRUS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CHARACTERIZATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; ENZYME INHIBITORS; GLUTAMIC ACID; GUANIDINES; HUMANS; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PROTEIN FOLDING; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0033897803     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00103-0     Document Type: Review

References (60)

1. Baigent S.J., Bethell R.C., McCauley J.W. Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro. Virology. 263:1999;323-338.
2. Bantia S., Ghate A.A., Ananth S.L., Babu Y.S., Air G.M., Walsh G.M. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob. Agents Chemother. 42:1998;801-807.
3. Bantia, S., Ananth, K., Andries, K., Horn, L., Parker, C., Chand, P., Babu, Y., 1999a. In vitro activity of the neuraminidase inhibitor RWJ-270201 (BCX-1812) against influenza virus. Second International Symposium on Influenza and other Respiratory viruses, Grand Cayman, Cayman Islands, December 10-12.
4. Bantia, S., Chand, P., Parker, C., Ananth, S., Horn, L., Kotian, P., Dehghani, A., Kattan, Y., Lin, T., Hutchinson, T., Montgomery, J., Kellog, D., Johnson, H., Viegas, T., Laver, G., Babu, Y., 1999b. In vivo activity of RWJ-270201 (BCX-1812), a novel and potent inhibitor of influenza neuraminidase. Second International Symposium on Influenza and other Respiratory viruses, Grand Cayman, Cayman Islands, December 10-12.
5. Barnett J.M., Cadman A., Burrell F.M., Madar S.H., Lewis A.P., Tisdale M., Bethell R. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology. 265:1999;286-295.
6. Bethell, R.C., Hart, G.J., Blick, T.J., Sahasrabudhe, A., McKimm-Breschkin, J.L., 1999. Biochemical methods for the characterization of influenza viruses with reduced sensitivity to 4-guanidino-Neu5Ac2en. In: Kinchington, D., Schinazi, R.F. (Eds.), Methods in Molecular Medicine, Humana Press, Totowa, NJ, pp. 367-374.
7. Blick T.J., Tiong T., Sahasrabudhe A., Varghese J.N., Colman P.M., Hart G.J., Bethell R.C., McKimm-Breschkin J.L. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology. 214:1995;475-484.
8. Blick T.J., Sahasrabudhe A., McDonald M., Owens I.J., Morley P.J., Fenton R.J., McKimm-Breschkin J.L. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology. 246:1998;95-103.
9. Burmeister W.P., Ruigrok R.W., Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11:1992;49-56.
10. Carr, J., Ives, J., Roberts, N.A., Tai, C.Y., Mendel, D.B., Kelly, L., Lambkin, R., Oxford, J., 1999. An oseltamivir treatment-selected influenza A/Wuhan/359/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo. Second International Symposium on Influenza and other Respiratory viruses, Grand Cayman, Cayman Islands, December 10-12.
11. Colacino J.M., Chirgadze N.Y., Garman E., Murti K.G., Loncharich R.J., Baxter A.J., Staschke K.A., Laver W.G. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology. 236:1997;66-75.
12. Covington, E., Mendel, D.B., Escarpe, P., Tai, C.Y., Soderbarg, K., Roberts, N.A., 1999. Phenotypic and genotypic assay of influenza neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir. Second International Symposium on Influenza and other Respiratory viruses, Grand Cayman, Cayman Islands, December 10-12.
13. Englund J.A., Champlin R.E., Wyde P.R., Kantarjian H., Atmar R.L., Tarrand J., Yousuf H., Regnery H., Klimov A.I., Cox N.J., Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin. Infect. Dis. 26:1998;1418-1424.
14. Goto H., Bethell R.C., Kawaoka Y. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 238:1997;265-272.
15. Grambas S., Bennett M.S., Hay A.J. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology. 191:1992;541-549.
16. Gubareva L.V., Bethell R., Hart G.J., Murti K.G., Penn C.R., Webster R.G. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70:1996a;1818-1827.
17. Gubareva, L.V., Bethell, R.C., Penn, C.R., Webster, R.G., 1996b. In vitro characterization of 4-guanidino-Neu5Ac2en-resistant mutants of influenza A virus. In: Brown, L.E., Hampson, A.W., Webster, R.G. (Eds.), Options for the control of Influenza III, Elsevier, Amsterdam, pp. 753-760.
18. Gubareva L.V., Robinson M.J., Bethell R.C., Webster R.G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71:1997;3385-3390.
19. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1998;1257-1262.
20. Gubareva, L.V., Schallon, D.W., Hayden, F.G., 1999. Activity of the neuraminidase inhibitor RWJ-270201 (BCX-1812) against influenza A and B viruses in the neuraminidase inhibition assays. Second International Symposium on Influenza and other Respiratory viruses, Grand Cayman, Cayman Islands, December 10-12.
21. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA. 275:1996;295-299.
22. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N. Engl. J. Med. 337:1997;874-880.
23. Houck P., Hemphill M., LaCroix S., Hirsh D., Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch. Intern. Med. 155:1995;533-537.
24. Kim C.U., Lew W., Williams M.A., Wu H., Zhang L., Chen X., Escarpe P.A., Mendel D.B., Laver W.G., Stevens R.C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41:1998;2451-2460.
25. Leigh M.W., Connor R.J., Kelm S., Baum L.G., Paulson J.C. Receptor specificity of influenza virus influences severity of illness in ferrets. Vaccine. 13:1995;1468-1473.
26. Lentz M.R., Webster R.G., Air G.M. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. Biochemistry. 26:1987;5351-5358.
27. Li W., Escarpe P.A., Eisenberg E.J., Cundy K.C., Sweet C., Jakeman K.J., Merson J., Lew W., Williams M., Zhang L., Kim C.U., Bischofberger N., Chen M.S., Mendel D.B. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:1998;647-653.
28. Martin J., Wharton S.A., Lin Y.P., Takemoto D.K., Skehel J.J., Wiley D.C., Steinhauer D.A. Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology. 241:1998;101-111.
29. McDonald, M., McKimm-Breschkin, J., Sahasrabudhe, A., Blick, T., 1998. Infectivity and drug sensitivity studies of zanamivir resistant HA variants of influenza virus in the mouse model. International Symposium on Influenza and other Respiratory viruses, Maui, Hawaii, December 7-10.
30. McDonald, M., Blick, T., Sahasrabudhe, A., McKimm-Breschkin, J.L., 1999. A comparison of influenza virus variants with haemagglutinin mutations at Thr155 which demonstrate resistance to neuraminidase inhibitors. Eleventh International Congress of Virology, Sydney, Australia, August 9-13, VP27. 23, p. 312.
31. McKimm-Breschkin J.L., Blick T.J., Sahasrabudhe A., Tiong T., Marshall D., Hart G.J., Bethell R.C., Penn C.R. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40:1996a;40-46.
32. McKimm-Breschkin, J.L., Blick, T.J., Sahasrabudhe, A., Varghese, J.N., Bethell, R.C., Hart, G.J., Penn, C.R., Colman, P.M., 1996b. Influenza virus variants with decreased sensitivity to 4-amino- and 4-guanidino-Neu5Ac2en. In: Brown, L.E., Hampson, A.W., Webster, R.G. (Eds.), Options for the Control of Influenza III, Elsevier, Amsterdam, pp. 726-734.
33. McKimm-Breschkin J.L., McDonald M., Blick T.J., Colman P.M. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino- Neu5Ac2en leads to instability of the enzyme. Virology. 225:1996c;240-242.
34. McKimm-Breschkin J.L., Sahasrabudhe A., Blick T.J., McDonald M., Colman P.M., Hart G.J., Bethell R.C., Varghese J.N. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 72:1998;2456-2462.
35. McKimm-Breschkin, J.L., Blick, T., McDonald, M., 1999a. Reassorting of influenza virus can alter both sensitivity to zanamivir and pathogenicity in vivo without the introduction of mutations. Second International Symposium on Influenza and other Respiratory viruses, Grand Cayman, Cayman Islands, December 10-12.
36. McKimm-Breschkin, J.L., McDonald, M., Sahasrabudhe, A., Blick, T., 1999b. Infectivity and drug sensitivity studies in the mouse model of zanamivir resistant HA variants of influenza virus. Eleventh International Congress of Virology, Sydney, Australia, August 9-13, VW27.03, p. 97.
37. McKimm-Breschkin, J.L., Sahasrabudhe, A., Blick, T., Jpwett. A. J., Bethell, R.C., 1999c. Virological methods for the generation and characterization of influenza viruses with reduced sensitivity to 4-guanidino-Neu5Ac2en. In: Kinchington, D., Schinazi, R.F. (Eds.), Methods in Molecular Medicine, Humana Press, Totowa, NJ, pp. 375-381.
38. Meindl P., Tuppy H. 2-Deoxy-2,3-dehydrosialic acids. 1. Synthesis and properties of 2-deoxy-2,3-dehydro-N-acylneuraminic acids and their methyl esters. Monstah Chem. 100:1969;1295-1306.
39. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen M.S., Bischofberger N., Kim C.U. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:1998;640-646.
40. Nobusawa E., Aoyama T., Kato H., Suzuki Y., Tateno Y., Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology. 182:1991;475-485.
41. Nobusawa E., Nakajima K. Amino acid substitution at position 226 of the hemagglutinin molecule of influenza (H1N1) virus affects receptor binding activity but not fusion activity. Virology. 167:1988;8-14.
42. Palese, P., Schulman, J.L., 1977. Inhibitors of viral neuraminidase as potential antiviral drugs. In: Osford, J.S. (Eds.), Chemoprophylaxis and Virus infections of the Upper Respiratory Tract, CRC, Cleveland, pp. 189-205.
43. Penn, C.R., Barnett, J.M., Bethell, R.C., Fenton, R., Gearing, K.L., Healy, N., Jowett, A.J., 1996. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of neuraminidase activity. In: Brown, L.E., Hampson, A.W., Webster, R.G. (Eds.), Options for Control of Influenza III, Elsevier, Amsterdam, pp. 735-740.
44. Rogers G.N., Paulson J.C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 127:1983;361-373.
45. Sahasrabudhe, A., Blick, T., McKimm-Breschkin, J.L., 1996. Influenza virus variants resistant to GG167 with mutations in the haemagglutinin. In: Brown, L.E., Hamson, A.W., Webster, R.G. (Eds.), Options for Control of Influenza III, Elsevier, Amsterdam, pp. 748-752.
46. Sahasrabudhe A., Lawrence L., Epa V.C., Varghese J.N., Colman P.M., McKimm-Breschkin J.L. Substrate, inhibitor, or antibody stabilizes the Glu 119 Gly mutant influenza virus neuraminidase. Virology. 247:1998;14-21.
47. Smith P.W., Sollis S.L., Howes P.D., Cherry P.C., Starkey I.D., Cobley K.N., Weston H., Scicinski J., Merritt A., Whittington A., Wyatt P., Taylor N., Green D., Bethell R., Madar S., Fenton R.J., Morley P.J., Pateman T., Beresford A. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides. J. Med. Chem. 41:1998;787-797.
48. Smith P.W., Robinson J.E., Evans D.N., Sollis S.L., Howes P.D., Trivedi N., Bethell R.C. Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone. Bioorg. Med. Chem. Lett. 9:1999;601-604.
49. Staschke K.A., Colacino J.M., Baxter A.J., Air G.M., Bansal A., Hornback W.J., Munroe J.E., Laver W.G. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology. 214:1995;642-646.
50. Tai C.Y., Escarpe P.A., Sidwell R.W., Williams M.A., Lew W., Wu H., Kim C.U., Mendel D.B. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:1998;3234-3241.
51. Taylor N.R., Cleasby A., Singh O., Skarzynski T., Wonacott A.J., Smith P.W., Sollis S.L., Howes P.D., Cherry P.C., Bethell R., Colman P., Varghese J. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 41:1998;798-807.
52. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:2000;45-55.
53. Varghese J.N., Laver W.G., Colman P.M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature. 303:1983;35-40.
54. Varghese J.N., McKimm-Breschkin J.L., Caldwell J.B., Kortt A.A., Colman P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins. 14:1992;327-332.
55. Varghese J.N., Epa V.C., Colman P.M. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci. 4:1995;1081-1087.
56. Varghese J.N., Smith P.W., Sollis S.L., Blick T.J., Sahasrabudhe A., McKimm-Breschkin J.L., Colman P.M. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure. 6:1998;735-746.
57. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
58. Weis W., Brown J.H., Cusack S., Paulson J.C., Skehel J.J., Wiley D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 333:1988;426-431.
59. Woods J.M., Bethell R.C., Coates J.A., Healy N., Hiscox S.A., Pearson B.A., Ryan D.M., Ticehurst J., Tilling J., Walcott S.M. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1993;1473-1479.
60. Yang P., Bansal A., Liu C., Air G.M. Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses. Virology. 229:1997;155-165.